State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, SAR, China.
Department of Thoracic Surgery, Guangzhou Institute of Respiratory Health and State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, China.
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.
Immune checkpoint blockade therapies that target CTLA-4 and PD-1/PD-L1 have ushered in a new era of cancer treatment. Nevertheless, a significant proportion of patients demonstrated primary or acquired resistance. Harnessing gut microbiota has been an emerging novel therapeutic strategy to overcome resistance. Here we summarized the current research status of gut microbiota in immune checkpoint blockade therapies, clinical trials, underlying mechanisms and challenges of microbiome research in checkpoint immunotherapy. Findings from preclinical models, standardized microbiome analysis and progress of multi-omic approaches may better disclose the interaction between gut microbiota and immune checkpoint inhibitors (ICIs) and traditional Chinese medicine can be a potential microbiome modulator to sensitize the response to ICIs.
免疫检查点阻断疗法靶向 CTLA-4 和 PD-1/PD-L1 为癌症治疗带来了新的时代。然而，相当一部分患者表现出原发性或获得性耐药。利用肠道微生物群已成为一种新的治疗策略，以克服耐药性。在这里，我们总结了肠道微生物群在免疫检查点阻断疗法中的研究现状、临床试验、潜在机制以及检查点免疫疗法中微生物组研究的挑战。临床前模型、标准化微生物组分析和多组学方法的进展可能会更好地揭示肠道微生物群与免疫检查点抑制剂（ICIs）之间的相互作用，而中药可能是一种潜在的微生物群调节剂，以增强对 ICI 的反应。
